Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinolazepam SCHEMBL415075 | 1.00 | OPRK1 (0.53) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL30338063 | 1.00 | OPRK1 (0.53) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL28142897 | 0.96 | OPRK1 (0.50) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7330064 | 0.90 | OPRK1 (0.67) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Doxefazepam SCHEMBL554909 | 0.88 | OPRK1 (0.57) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Doxefazepam SCHEMBL31128398 | 0.88 | OPRK1 (0.57) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7320833 | 0.87 | OPRK1 (0.66) | OPRK1CHRM2ADRA2APDE4DKCNH2 | |
| SCHEMBL7323323 | 0.85 | CCKBR (0.49) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7332842 | 0.85 | CCKBR (0.47) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL28086502 | 0.84 | OPRK1 (0.47) | OPRK1CHRM2ADRA2APDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250104836-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | POP TEST ABUSE DETERRENT TECH LLC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12205696-B2 | Drug device configured for wireless communication | POP TEST ABUSE DETERRENT TECHNOLOGY LLC (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230060681-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | POP TEST ABUSE DETERRENT TECH LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11527315-B2 | Drug device configured for wireless communication | POP TEST ABUSE DETERRENT TECHNOLOGY LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210246133-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2895476-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| CN-104619701-A | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | HOFFMANN LA ROCHE | 2015-05-13 | — | — | CN | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| US-20140256709-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8729070-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2014-05-20 | — | — | US | disclosed |
| WO-2014040969-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-20120301405-A1 | Simple Mechanical Procedure and Product for Deterring Substance Abuse. | KULLI JOHN C (US) | 2012-11-29 | — | — | US | disclosed |
| US-20110054038-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2011-03-03 | — | — | US | disclosed |
| US-20090005367-A1 | COMPOSITION AND METHOD FOR TREATING ALCOHOLISM AND OTHER SUBSTANCE ADDICTIONS | THE UNIVERSITY OF CHICAGO | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246133-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | OPRK1 17/4885CHRM2 22/4885ADRA2A 116/4885 |
| US-12205696-B2 | Drug device configured for wireless communication | CYP2D6, CYP2B6, PTGDR | OPRK1 306/4885CHRM2 311/4885ADRA2A 200/4885 |
| US-20230060681-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | CYP2D6, CYP2B6, PTGDR | OPRK1 306/4885CHRM2 311/4885ADRA2A 200/4885 |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | OPRK1 2260/4885CHRM2 4054/4885ADRA2A 2396/4885 |
| US-11527315-B2 | Drug device configured for wireless communication | CYP2D6, CYP2B6, PTGDR | OPRK1 306/4885CHRM2 311/4885ADRA2A 200/4885 |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | OPRK1 17/4885CHRM2 22/4885ADRA2A 116/4885 |
| US-20250104836-A1 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION | CYP2D6, CYP2B6, PTGDR | OPRK1 306/4885CHRM2 311/4885ADRA2A 200/4885 |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | OPRK1 17/4885CHRM2 22/4885ADRA2A 116/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | OPRK1 17/4885CHRM2 22/4885ADRA2A 116/4885 |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HCRTR2, TPH2, CNR2 | OPRK1 19/4885CHRM2 16/4885ADRA2A 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.